Positive data for hepatitis C DNA vaccine
Tripep reports positive data for hepatitis C DNA vaccine using Inovio's DNA delivery system
Inovio Biomedical Corporation (INO) announced that its partner, Tripep AB, Sweden, has reported added positive preclinical results showing its ChronVac-C DNA vaccine using Inovio's MedPulser DNA delivery system produced a strong immune response against hepatitis C virus (HCV) in a large animal model.
Ongoing toxicity studies of ChronVac-C delivered using Inovio's electroporation-based system showed that the combination induces a humoral response in rabbits that is comparable to results previously observed in mice.
Hepatitis is a disease characterized by inflammation of the liver. Hepatitis C virus (HCV) is a major cause of acute hepatitis. HCV is spread primarily by direct contact with human blood, the major causes worldwide being the use of unscreened blood transfusions, and re-use of needles and syringes that have not been adequately sterilized. As many as 70-90% of newly infected patients may progress to develop chronic infection (WHO: 2002). Of those with chronic liver disease, 5-20% may develop cirrhosis. About 5% of infected persons may die from the consequences of long term infection (due to liver cancer or cirrhosis).
Globally, an estimated 170 million people are chronically infected with HCV, which represents a reservoir sufficiently large for HCV to persist, and 3 to 4 million persons are newly infected each year. In the U.S., while new incidences of HCV have dropped dramatically, an estimated 4.1 million (1.6%) Americans have been infected with HCV, of whom 3.2 million are chronically infected (U.S. Centers for Disease Control and Prevention: 2006).
ChronVac-C is designed to be a therapeutic DNA vaccine that can stimulate the body's immune system. Animal experiments have demonstrated that ChronVac-C vaccination activates B cells and T-cells, the latter being regarded as the most significant to clearing the chronic infection relating to hepatitis C, that killed cells producing HCV protein. In humans, the ChronVac-C DNA plasmid would be injected into muscle tissue, where vaccinations are usually given, and taken up by muscle cells with the assistance of Inovio's electroporation-based DNA delivery system. These muscle cells would be expected to then produce predetermined proteins that may activate the body's immune system to attack all cells producing HCV proteins.
Tripep AB is a Swedish biotechnology research company that develops and commercialises candidate drugs based on patented and proprietary technologies. Its main focuses are research and clinical development of ChronVac-C.
Inovio Biomedical Corporation is a late stage biomedical company focused on commercializing its proprietary Selective Electrochemical Tumor Ablation (SECTA) therapy, which is a local treatment for solid tumors, with selective killing of cancer cells while preserving surrounding healthy tissue.
Inovio Biomedical Corporation (INO) announced that its partner, Tripep AB, Sweden, has reported added positive preclinical results showing its ChronVac-C DNA vaccine using Inovio's MedPulser DNA delivery system produced a strong immune response against hepatitis C virus (HCV) in a large animal model.
Ongoing toxicity studies of ChronVac-C delivered using Inovio's electroporation-based system showed that the combination induces a humoral response in rabbits that is comparable to results previously observed in mice.
Hepatitis is a disease characterized by inflammation of the liver. Hepatitis C virus (HCV) is a major cause of acute hepatitis. HCV is spread primarily by direct contact with human blood, the major causes worldwide being the use of unscreened blood transfusions, and re-use of needles and syringes that have not been adequately sterilized. As many as 70-90% of newly infected patients may progress to develop chronic infection (WHO: 2002). Of those with chronic liver disease, 5-20% may develop cirrhosis. About 5% of infected persons may die from the consequences of long term infection (due to liver cancer or cirrhosis).
Globally, an estimated 170 million people are chronically infected with HCV, which represents a reservoir sufficiently large for HCV to persist, and 3 to 4 million persons are newly infected each year. In the U.S., while new incidences of HCV have dropped dramatically, an estimated 4.1 million (1.6%) Americans have been infected with HCV, of whom 3.2 million are chronically infected (U.S. Centers for Disease Control and Prevention: 2006).
ChronVac-C is designed to be a therapeutic DNA vaccine that can stimulate the body's immune system. Animal experiments have demonstrated that ChronVac-C vaccination activates B cells and T-cells, the latter being regarded as the most significant to clearing the chronic infection relating to hepatitis C, that killed cells producing HCV protein. In humans, the ChronVac-C DNA plasmid would be injected into muscle tissue, where vaccinations are usually given, and taken up by muscle cells with the assistance of Inovio's electroporation-based DNA delivery system. These muscle cells would be expected to then produce predetermined proteins that may activate the body's immune system to attack all cells producing HCV proteins.
Tripep AB is a Swedish biotechnology research company that develops and commercialises candidate drugs based on patented and proprietary technologies. Its main focuses are research and clinical development of ChronVac-C.
Inovio Biomedical Corporation is a late stage biomedical company focused on commercializing its proprietary Selective Electrochemical Tumor Ablation (SECTA) therapy, which is a local treatment for solid tumors, with selective killing of cancer cells while preserving surrounding healthy tissue.
0 comments:
Post a Comment